| A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
|
| A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
|
| To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
|
| Not Provided
|
| Interventional
|
| Phase 3
|
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|
| Glaucoma
|
|
|
|
|
| Not Provided
|
| |
| Completed
|
| 139
|
| 120
|
| November 2009
|
| November 2009 (Final data collection date for primary outcome measure)
|
|
Inclusion Criteria:
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria:
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
|
| Sexes Eligible for Study: |
All |
|
| 36 Weeks to 18 Years (Child, Adult)
|
| No
|
|
Contact information is only displayed when the study is recruiting subjects
|
| Belgium, Colombia, Czech Republic, France, Germany, India, Italy, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, Spain, Ukraine, United Kingdom, United States
|
|
|
| |
| NCT00716859
|
| A6111137
|
| Yes
|
| Not Provided
|
| Not Provided
|
| Director, Clinical Trial Disclosure Group, Pfizer Inc
|
| Pfizer
|
| Not Provided
|
| Study Director: |
Pfizer CT.gov Call Center |
Pfizer |
|
| Pfizer
|
| January 2011
|
